Huvepharma extends deadline after getting ratings
Bankers now hope to complete a €275m acquisition loan for Bulgarian drugs firm Huvepharma this week after extending the deadline to wait for Moody's and Standard & Poor's to provide ratings.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article:
- ✔ 4,000 annual insights
- ✔ 700+ notes and long-form analyses
- ✔ 4 capital markets databases
- ✔ Daily newsletters across markets and asset classes
- ✔ 2 weekly podcasts